A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer

Sébastien Taurin(University of Otago), Khaled Greish(University of Otago)
International Journal of Nanomedicine
January 1, 2016
Cited by 20


Related Papers